Pfizer Gets Marketing Authorization In UK For Atopic Dermatitis Drug, Cibinqo

Pfizer Inc. (PFE) on Thursday said it received marketing authorization in U.K. for its atopic dermatitis drug, Cibinqo.

Cibinqo (abrocitinib), a Janus kinase 1 (JAK1) inhibitor, has been authorized by UK's Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of moderate to severe atopic dermatitis in adults and adolescents aged 12 years and over, who are candidates for systemic therapy.

Atopic dermatitis is a chronic skin condition characterized by dry, itchy skin.

Regulatory applications for abrocitinib have been submitted to countries around the world for review, including the United States, Australia, Japan, and the European Union, Pfizer said.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Goldman Sachs Group, Inc. (GS) reported that its third quarter net earnings applicable to common shareholders increased 63 percent year-on-year. Net revenues were also significantly higher reflecting significantly higher net revenues in Investment Banking, Global Markets and Consumer & Wealth Management,... Butterball, LLC recalled about 14,107 pounds of ground turkey products for potential contamination with foreign materials, specifically blue plastic material, the U.S. Department of Agriculture's Food Safety and Inspection Service (FSIS) said in a statement. Specialized Bicycle Components, Inc. is recalling about 6,900 units of Tarmac SL7 Bicycles and Framesets for potential risk of fall and injury hazard, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said the bicycle's fork steerer tube can crack or break after harsh impact such as hitting a deep pothole or other stress event, posing fall and injury hazards.
Follow RTT